WCLC

Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC

Retrieved on: 
fredag, december 10, 2021
Ligand, FDA, Infection, Lung cancer, Junshi, Esophageal cancer, Cancer, Risk, HIV disease progression rates, Breast, NDA, Review, Food, National Medical Products Administration, PD-L1, World, Esophagus, United, NPC, Stomach, Lung, SSE, Pharynx, NSCLC, GLOBE, Safety, Mortality, Microbiology, IDMC, EUA, Blas, PD-1, New Drug Application, PFS, Shanda, NMPA, Eli Lilly, WCLC, Medicine, Patient, Peking Union Medical College, Kidney, US Foods, R & D, Fast Track, Bamlanivimab, Cisplatin, Breakthrough therapy, PD-L2, Bamlanivimab/etesevimab, Marketing, Mucosal melanoma, Severe acute respiratory syndrome coronavirus 2, Liver, Therapy, World Health Organization, Progression-free survival, Conference, BLA, OS, ALK, HKEX, Skin, Autoimmunity, Pharmaceutical industry

The study enrolled 465 NSCLC patients in 63 centers in China, among which 220 were squamous NSCLC patients and 245 were non-squamous NSCLC patients.

Key Points: 
  • The study enrolled 465 NSCLC patients in 63 centers in China, among which 220 were squamous NSCLC patients and 245 were non-squamous NSCLC patients.
  • Existing domestic and overseas studies have shown that monotherapy or combination chemotherapy of anti-PD-(L)1 monoclonal antibody has already become new standard for the first-line treatment of NSCLC.
  • Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.
  • Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

FDA Approves NGS-Based Companion Diagnostic for EGFR Exon20 Insertion Mutant Non-Small Cell Lung Cancer Tumor Tissue

Retrieved on: 
torsdag, december 9, 2021
Food and Drug Administration, Thermo Fisher Scientific, Research, Laboratory, Technology, Lung cancer, ROS1, NGS, Conference, Disease, Pharmaceutical Services Negotiating Committee, Patheon, Gene, Food, Fisher Scientific, International Association, PPD, Mindful Scientific Inc., WCLC, Patient, Biomarker, Cancer, Invitrogen, Large-cell lung carcinoma, Science, Government, Cholangiocarcinoma, Janssen, RET, BRAF, Ministry of Health, Labour and Welfare, Applied Biosystems, FDA, Neoplasm, EGFR, Cdx, ALK, List of health departments and ministries, MHLW, Ministry, European, Vaccine, Pharmaceutical industry

We look forward to expanding registration of the test as a companion diagnostic for RYBREVANT globally to help improve outcomes for more patients."

Key Points: 
  • We look forward to expanding registration of the test as a companion diagnostic for RYBREVANT globally to help improve outcomes for more patients."
  • This is the second approval for Oncomine Dx Target Test as a CDx for EGFR Exon20 insertion mutant patients and the 12th NSCLC global approval overall.
  • Underdiagnosis of EGFR Exon 20 insertion mutation variants: estimates from NGS-based real-world datasets.
  • Oral presentation presented at: International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer Singapore (WCLC 2020); January 28-31, 2021; Worldwide Virtual Event.

New Phase III Data Support the Benefit of Genentech’s Tecentriq in Early-stage Lung Cancer

Retrieved on: 
måndag, september 20, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, ITT, Safety, Food, Oncology, Nominal interest rate, Neoplasm, Breast, WCLC, RO, Treatment of lung cancer, Carboplatin, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Recurrence, Congress, Conference, SCLC, FDA, Guideline, Cancer, Lung cancer, Hoffmann-La Roche, European Society for Medical Oncology, Population, ROG, Head, Immune system, DFS, Phase, NSCLC, Death, Stage, International Association, PD-1, Large-cell lung carcinoma, Paclitaxel, Disease, Risk, Bevacizumab, PD, BSC, Priority review, American Cancer Society, Etoposide, PD-L1, Tissue, Platinum, ESMO, UICC, Skin, Lung, Pharmaceutical industry, Health insurance, Medical imaging, Uranium, Vaccine, the IMpower010 study, lung cancer, Tecentriq® (atezolizumab), Genentech in cancer immunotherapy, Genentech in lung cancer, Genentech, THE IMPOWER010 STUDY, LUNG CANCER, TECENTRIQ® (ATEZOLIZUMAB), GENENTECH IN CANCER IMMUNOTHERAPY, GENENTECH IN LUNG CANCER, GENENTECH

Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.

Key Points: 
  • Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.
  • IMpower010 shows how, for the first time, a cancer immunotherapy may help many of these patients live longer without their disease returning.
  • The data presented at ESMO and WCLC further contribute to our understanding of Tecentriq in this treatment setting.
  • Tecentriq has previously shown clinically meaningful benefit in various types of lung cancer, with five currently approved indications in markets around the world.

Biodesix Announces Abstracts Presented During the IASLC 2021 World Conference on Lung Cancer

Retrieved on: 
torsdag, september 16, 2021
Science, Other Science, Biotechnology, Research, Oncology, Health, Infectious Diseases, Other Health, Immunotherapy, Diagnosis, 2021 Essex County Council election, WCLC, Biotechnology, Form 10-K, Lung cancer, CEO, Forward-looking statement, Conference, Patient, Company, Degenerative disease, Private Securities Litigation Reform Act, Blood, Malignancy, Nasdaq, Risk, Annual report, Survival, Physician, Large-cell lung carcinoma, ICI, COVID-19, KRAS, NSCLC, International Association, Triage, Intelligence, Lung, Kirin-Amgen Inc v Hoechst Marion Roussel Ltd, Artificial intelligence, GenScript Biotech, Medical imaging, Pharmaceutical industry, Risk management

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).

Key Points: 
  • Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced that two abstracts highlighting proteomic and genomic data based on their diagnostic tests were presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC).
  • The authors point out that while immunotherapy is very effective treating many patients with lung cancer, not all patients with lung cancer benefit.
  • These abstracts highlight the effectiveness of our approach in utilizing multiple technologies to determine the best treatment plans as rapidly as possible for patients with lung cancer.
  • The blood based Biodesix Lung Reflex strategy for lung cancer patients integrates the GeneStrat and VeriStrat tests to support treatment decisions with results in 36 hours, expediting time to treatment.

EQRx Announces Presentation of Updated Data from Pivotal Phase 3 Study of Anti-PD-L1 Antibody Sugemalimab in Combination with Chemotherapy as a First-Line Treatment for Stage IV NSCLC

Retrieved on: 
tisdag, september 14, 2021
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Conference, Safety, WCLC, Patient, International Association, Lung cancer, PFS, Lung, NSCLC, Pharmaceutical industry, Lung Cancer, GEMSTONE-302, Sugemalimab, EQRx, LUNG CANCER, GEMSTONE-302, SUGEMALIMAB, EQRX

GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating the efficacy and safety of the anti-PD-L1 antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer (NSCLC).

Key Points: 
  • GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating the efficacy and safety of the anti-PD-L1 antibody sugemalimab in combination with chemotherapy as a first-line treatment for patients with Stage IV non-small cell lung cancer (NSCLC).
  • We look forward to more mature OS data from GEMSTONE-302 as well as continued regulatory discussions for sugemalimab in multiple countries.
  • Details of the presentation are as follows:
    Session: MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?
  • Subgroup analysis showed clinical benefit regardless of PD-L1 expression level or pathologic subtype in patients with Stage IV NSCLC.

UKLS Trial Meta-Analysis Confirms that Low Dose CT Screening for Lung Cancer Reduces Mortality

Retrieved on: 
måndag, september 13, 2021
WCLC, Association, COPD, LLP, Lung cancer, University, Professor, Conference, Bronchitis, Journal of Thoracic Oncology, Asbestosis, Cancer, Tuberculosis, Tobacco, Pipe smoking, Clinical trial, Mortality, Respiratory disease, Physician, Pneumonia, International Association, Randomized controlled trial, Meta-analysis, University of Liverpool, Death, Wald, History, Diagnosis, Lung, Research, Awareness, Smoking, Medical imaging, Pharmaceutical industry

DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.

Key Points: 
  • DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.
  • Previous studies, such as the National Lung Cancer Screening Trial and The NELSON LDCT screening trial, provided evidence of a statistically significant reduction (20%, 24% respectively) in lung cancer mortality.
  • Results from these nine randomized controlled trials were included in the meta-analysis indicated a significant reduction in lung cancer mortality.
  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.

UKLS Trial Meta-Analysis Confirms that Low Dose CT Screening for Lung Cancer Reduces Mortality

Retrieved on: 
måndag, september 13, 2021
WCLC, Association, COPD, LLP, Lung cancer, University, Professor, Conference, Bronchitis, Journal of Thoracic Oncology, Asbestosis, Cancer, Tuberculosis, Tobacco, Pipe smoking, Clinical trial, Mortality, Respiratory disease, Physician, Pneumonia, International Association, Randomized controlled trial, Meta-analysis, University of Liverpool, Death, Wald, History, Diagnosis, Lung, Research, Awareness, Smoking, Medical imaging, Pharmaceutical industry

DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.

Key Points: 
  • DENVER, Sept. 13, 2021 /PRNewswire/ --Low-dose CT lung cancer (LDCT) screening is associated with a 16 percent relative reduction in lung cancer mortality, when compared against a non-LDCT control arm, according to research presented by Professor John Field and the United Kingdom Cancer Screening Trial (UKLS) Team today at the IASLC 2021 World Conference on Lung Cancer.
  • Previous studies, such as the National Lung Cancer Screening Trial and The NELSON LDCT screening trial, provided evidence of a statistically significant reduction (20%, 24% respectively) in lung cancer mortality.
  • Results from these nine randomized controlled trials were included in the meta-analysis indicated a significant reduction in lung cancer mortality.
  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies.

Almost two thirds of thoracic oncologists used telehealth for the first-time during pandemic: IASLC survey

Retrieved on: 
söndag, september 12, 2021

Telehealth and telemedicine emerged as essential communications tools during the COVID-19 pandemic as alternatives to face-to-face consultation between patients and physicians.

Key Points: 
  • Telehealth and telemedicine emerged as essential communications tools during the COVID-19 pandemic as alternatives to face-to-face consultation between patients and physicians.
  • Physicians felt that telehealth was most appropriate during surveillance (94.1%) and least so for initial diagnosis (69.8%).
  • Most felt that patients were receptive to telehealth (55.3%), however, clinicians worried that its use would increase healthcare disparities (29.7%).
  • Although, telehealth has been widely adopted, issues remain such as healthcare access, point of use in the care pathway and telehealth platform selection."

Neoadjuvant Atezolizumab in Combination with Cisplatin/Pemetrexed and as Maintenance for Resectable Pleural Mesothelioma Meets Safety Criteria

Retrieved on: 
söndag, september 12, 2021

Safety was defined as no Grade 4-5 immune-related adverse event; feasible if 18/24 (75%) received at least one dose of maintenance therapy. Patients were divided into two cohorts --the pleurectomy/decortication cohort or the extrapleural penomonectomy cohort.

Key Points: 
  • Safety was defined as no Grade 4-5 immune-related adverse event; feasible if 18/24 (75%) received at least one dose of maintenance therapy.
  • Patients received four cycles of neoadjuvant cisplatin and pemetrexed plus atezolizumab (CPA), resection, then radiation (EPP cases only), followed by one year of maintenance atezolizumab.
  • Twenty-eight eligible patients were enrolled (Nov 2017 - May 2020); 25 received at least two cycles of neoadjuvant CPA, 18 underwent surgery, and 15 received maintenance atezolizumab.
  • "Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria," said Dr. Tsao.

IMpower010 Shows Significantly Improved Disease-free Survival for Patients with Resected Stage II to III Non-Small Cell Lung Cancer

Retrieved on: 
lördag, september 11, 2021

The Phase III IMpower010 trial evaluating atezolizumab vs best supportive care after surgical resection and adjuvant chemotherapy met its primary endpoint showing significant disease-free survival improvement for patients with stage II-IIIA (UICC v7) non-small cell lung cancer.

Key Points: 
  • The Phase III IMpower010 trial evaluating atezolizumab vs best supportive care after surgical resection and adjuvant chemotherapy met its primary endpoint showing significant disease-free survival improvement for patients with stage II-IIIA (UICC v7) non-small cell lung cancer.
  • The primary endpoint of investigator-assessed disease-free survival was tested hierarchically in the PD-L1 TC 1% (SP263) stage II-IIIA population, all-randomized stage II-IIIA population, and ITT population (stage IB-IIIA).
  • "Patients who participated in the IMpower010 trial, including patients with nodal involvement, saw benefit across disease stages (stage II-IIIA sub-populations)," Altorki reported.
  • The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe.